Derma Sciences (NASDAQ: DSCI) and Mazor Robotics (NASDAQ:MZOR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Derma Sciences and Mazor Robotics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Derma Sciences 0 1 0 0 2.00
Mazor Robotics 2 5 1 0 1.88

Mazor Robotics has a consensus price target of $39.60, indicating a potential downside of 29.71%. Given Mazor Robotics’ higher possible upside, analysts clearly believe Mazor Robotics is more favorable than Derma Sciences.


This table compares Derma Sciences and Mazor Robotics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Derma Sciences -20.97% -17.10% -12.43%
Mazor Robotics -28.80% -22.68% -18.29%

Insider and Institutional Ownership

58.9% of Derma Sciences shares are owned by institutional investors. Comparatively, 26.5% of Mazor Robotics shares are owned by institutional investors. 9.9% of Derma Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Derma Sciences and Mazor Robotics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Derma Sciences N/A N/A N/A ($0.31) -22.58
Mazor Robotics $36.38 million 39.52 -$18.66 million ($0.71) -79.35

Derma Sciences has higher earnings, but lower revenue than Mazor Robotics. Mazor Robotics is trading at a lower price-to-earnings ratio than Derma Sciences, indicating that it is currently the more affordable of the two stocks.


Derma Sciences beats Mazor Robotics on 7 of the 10 factors compared between the two stocks.

Derma Sciences Company Profile

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications. Its Renaissance System and its predecessor are used in a number of spine surgeries, including fusion, correction of spinal deformities, biopsy collection, tumor excision and cement augmentations. Furthermore the Company developed the Renaissance Brain Module, an application of its Renaissance System that provides control over the insertion of surgical instruments during brain surgery.

Receive News & Ratings for Derma Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences and related companies with's FREE daily email newsletter.